2011 Volume 63 Issue 3 Pages 277-283
Treatment with pegylated liposomal doxorubicin (PLD)was initiated for heavily treated patients with recurrent ovarian cancer (n=13)and peritoneal cancer (n=4)from July 2009 through June 2010 in our hospital. We experienced complete response in 1 case and partial response in 3 cases, with a response rate of 27% (4/15). Adverse effects included stomatitis (53%), hand-foot syndrome (71%), and myelosuppression (88%), but were not severe. The period from onset of the primary disease until PLD treatment (> 2 years)correlated with the anti-tumor effect of PLD, which implies that tumors in which previous chemotherapy had been effective are sensitive to PLD. Stomatitis also correlated with a tumor response (p<0.05). Although the overall anti-tumor effect in three cases that needed periodic removal of ascites prior to the PLD treatment was progressive disease, the retention of ascites in these three cases decreased prominently with the intravenous administration of PLD. Further study is desired to establish a protocol for the treatment of recurrent ovarian and peritoneal cancer by accumulating clinical data on the use of PLD in Japan from now on. [Adv Obstet Gynecol, 63(3) : 277-283, 2011 (H23.8)]
